Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapaquistat Acetate with Rosuvastatin in Primary Hypercholesterolemia
NCT00249912Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2005
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of lapaquistat in hypercholesterolemia (3 arms), sponsored by Takeda. Primary endpoint: Change from Baseline in Low Density Lipoprotein cholesterol at 24 weeks. Started Oct 2005; status: completed.
02
Drugs
lapaquistat
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00249912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00249912.